证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2025-003 投资者关系活动 类别 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■其他 （电话会议） 参与单位名称及 人员姓名 东吴证券医药团队、中金证券医药团队、平安证券医药团队、开源证 券医药团队、中信证券医药团队、信达证券医药团队、天风证券医药 团队、中泰证券医药团队、西部证券医药团队、中邮证券医药团队、 农银国际医药团队及多家券商、公募基金、私募基金经理、研究员参 与调研 时间 2025 年 8 月 15 日 15:30-16:30 地点 电话会议 上市公司接待人 员姓名 副总经理、董事会秘书：刘晓杰 副总经理：吴晓明 证券事务代表：李季 投资者关系活动 主要内容介绍 2025 年半年报解读及近期公司经营发展情况交流 会议纪要主要内容： 问题一：2025 年半年度基本情况介绍 答： （一）经营业绩 公司实现营业收入 13.84 亿元，同比下降 2.60%。归属于上市公司股东的净利润 0.89 亿元，同比下降 20.70%。 核药业务板块销售收入 5. ...

瑞财经 刘治颖 8月14日，东诚药业(SZ002675)发布2025年半年度报告，营收净利双降。 报告期内，公司实现营业收入13.84亿元，同比下降2.60%。归属于上市公司股东的净利润0.89亿元，同比下降20.70%。 | | 本报告期 | 上年同期 | 本报告其 | | --- | --- | --- | --- | | 营业收入(元) | 1, 383, 711, 882. 86 | 1, 420, 711, 375. 17 | | | 归属于上市公司股东的净利 | 88, 652, 457. 27 | 111, 789, 792. 00 | | | 润(元) | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 80, 469, 519. 66 | 105, 746, 696. 14 | | | (元) | | | | | 经营活动产生的现金流量净 | 267, 606, 275. 05 | -17, 786, 859, 20 | | | 额(元) | | | | | 基本每股收益(元/股) | 0. 1075 | 0. 1356 | | | 稀释每股收益(元/股) | 0. 10 ...

Group 1 - The People's Bank of China emphasizes the implementation of a moderately loose monetary policy to meet the financing needs of the real economy and support key areas such as technological innovation and consumption [2] - The Ministry of Finance reports that from January to April, the national general public budget revenue reached 80,616 billion yuan, a year-on-year decrease of 0.4%, with the decline narrowing by 0.7 percentage points compared to the first quarter [3] - In April, tax revenue increased by 1.9% year-on-year, marking the first month of positive growth this year, while the total tax revenue from January to April was 65,556 billion yuan, down 2.1% year-on-year [4] Group 2 - The Ministry of Finance announces that the securities transaction stamp duty for January to April was 53.5 billion yuan, a year-on-year increase of 57.8% [5] - The National Energy Administration reports that the total electricity consumption in April was 7,721 billion kilowatt-hours, a year-on-year increase of 4.7% [6] - The National Development and Reform Commission states that most policies aimed at stabilizing employment and the economy are expected to be implemented by the end of June [8] Group 3 - The National Development and Reform Commission highlights the need to address "involution" competition that distorts market mechanisms and disrupts fair competition [9] - The China Automobile Industry Association reports that the top ten car manufacturers sold 2.502 million vehicles from January to April, accounting for 68.7% of total car sales [10] - A joint document from the Central Cyberspace Affairs Commission, the National Development and Reform Commission, and the Ministry of Industry and Information Technology outlines goals for IPv6 deployment by 2025, including reaching 850 million active users [11] Group 4 - Various companies are making significant moves, such as Zhaoyi Innovation planning to issue H-shares and list on the Hong Kong Stock Exchange, and several companies announcing share repurchase plans [13] - The Ministry of Finance reports that the total assets and loan growth rates of state-owned banks have slightly declined compared to 2024, but remain relatively high [14] - Zhongtai Securities discusses the logic behind the recent rise in bank stocks, indicating a strong rationale for continued investment in this sector [15]

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its product, Nadroparin Calcium Injection, from the Belarusian drug regulatory authority, valid until March 13, 2030. This approval is expected to positively impact the company's expansion into overseas markets [1]. Group 1 - The drug Nadroparin Calcium Injection is primarily used for the treatment of moderate to high-risk venous thromboembolism and the prevention of venous thromboembolic diseases [1]. - The registration approval in Belarus represents a significant step for the company in terms of international market penetration [1].